ClinVar Miner

Submissions for variant NM_000251.3(MSH2):c.2005+1G>C

dbSNP: rs267607986
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
International Society for Gastrointestinal Hereditary Tumours (InSiGHT) RCV000076338 SCV000107363 likely pathogenic Lynch syndrome 2019-06-21 reviewed by expert panel curation Interrupts canonical donor splice site
Ambry Genetics RCV003162495 SCV003910171 pathogenic Hereditary cancer-predisposing syndrome 2023-03-09 criteria provided, single submitter clinical testing The c.2005+1G>C intronic pathogenic mutation results from a G to C substitution one nucleotide after coding exon 12 of the MSH2 gene. This variant was reported in a proband whose family history met Amsterdam criteria for Lynch syndrome; however, microsatellite instability (MSI) testing in her endometrial cancer was negative (Overbeek LI et al. Br J Cancer, 2007 May;96:1605-12). Another alteration impacting the same donor site (c.2005+1G>A) has been detected in Lynch syndrome families or in probands whose Lynch syndrome-associated tumors demonstrated high MSI and/or loss of MSH2/MSH6 expression by immunohistochemistry (Ambry internal data; Bécouarn Y et al. Gastroenterol. Clin. Biol. 2005;29:667-75; Bonadona V et al. JAMA 2011 Jun;305:2304-10). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and will result in the creation or strengthening of a novel splice donor site; however, direct evidence is insufficient at this time (Ambry internal data). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation.
Myriad Genetics, Inc. RCV003452872 SCV004186623 likely pathogenic Lynch syndrome 1 2023-08-04 criteria provided, single submitter clinical testing This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.